News

MilliporeSigma Introduces Mobius® Power MIX 2000 for Difficult-to-Mix Biopharm Ingredients

MilliporeSigma’s Mobius® Power MIX 2000 single-use mixing system is engineered with advanced technology to effectively handle difficult-to-mix buffers, culture media powders and other pharmaceutical ingredients. The Mobius® Power MIX achieves a strong vortex using an impeller design and motor based on magnetically-coupled NovAseptic® technology, a proven mixing technology in stainless steel tanks. The Power MIX 2000 provides accessible, sterile zero deadleg sampling directly from the mixing container. A Probe Port allows for insertion of either a reusable probe for non-aseptic processes or a…

20161005_182412

BioProcess International Announces Winners of the 2016 BioProcess International Awards

BioProcess International magazine today announced the winners for the 2016 BioProcess International Awards. The awards celebrate the outstanding achievements, collaborations, business strategies, social corporate responsibility and technology applications that will allow the industry to deliver better, more effective treatments to a global patient base. Winners and finalists were honored and recognized by their peers during a very entertaining and exciting awards dinner and ceremony Wednesday evening, 5 October at the Boston Convention and Exhibition Center in Boston, MA. “The BioProcess…

Bio-Rad Launches Nuvia™ IMAC Affinity Resin for Process Scale Purifications at Bioprocess International Conference and Exhibition 2016

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) released Nuvia™ IMAC Resin, an immobilized metal affinity chromatography resin optimized for use from lab scale through pilot studies to process-scale manufacturing, at the 2016 Bioprocess International Conference and Exhibition, Boston, Oct. 4–7. Bio-Rad (Booth #1129) will also exhibit a host of customizable workflows designed to simplify and speed up drug discovery and development, including automated multicolumn protein purification, host cell protein and host cell DNA analysis, and CRISPR/Cas9 transfection and monitoring. A…

Biologics candidate manufactured using Ajinomoto Co., Inc.’s CORYNEX® Protein Expression System enters clinical trials for the first time

Ajinomoto Althea, Inc. (“Althea”) announced that a biologics candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using CORYNEX® Protein Expression System, has entered phase I clinical trials. The CORYNEX® system of Ajinomoto Co., Inc. (“Ajinomoto Co.”) is a proprietary protein expression platform that combines the best attributes of mammalian and microbial systems. It greatly simplifies the processes to produce and purify recombinant proteins resulting in reduced production costs and greatly speed time to market. The…

Tosoh Bioscience Introduces TOYOPEARL® Sulfate-650F Process Chromatography Resin

Tosoh Bioscience LLC, a provider of chromatographic resins for the purification of biopharmaceutical drugs in commercial manufacturing processes, today announced the introduction of TOYOPEARL Sulfate-650F, a strong cation exchange resin that exhibits high salt tolerance. TOYOPEARL Sulfate-650F resin is now available for sale in the Americas from Tosoh Bioscience LLC. TOYOPEARL Sulfate-650F resin allows for lowered operating costs by offering higher dynamic binding capacities for IgG. This resin can easily achieve a dynamic binding capacity of >120 g/L of monoclonal…

Thermo_Japan

Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan

To help meet increasing demand for cell and gene therapy clinical trial support around the globe, Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan. This expansion enables its customers to seamlessly conduct clinical trials across multiple geographies and provides patients around the world with access to life changing therapies. As a leading service provider to the cell and gene therapy community, Fisher BioServices is uniquely positioned…

Sartocon self-contained filter loop assembly

Sartorius Stedim Biotech launches two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane

Sartorius Stedim Biotech (SSB), a leading international supplier for the biopharmaceutical industry, today announced its polyethersulfone membrane (PESU) is now integrated into two new, sterile Sartocon® benchtop and production scale filtration assemblies. Using these assemblies guarantees rapid and safe ultrafiltration of biologics and vaccines. Due to the fully enclosed design, the Sartocon® assemblies are ideal for safely purifying vaccines and recombinant proteins, as well as monoclonal antibody manufacturing. This makes them suitable for use in cGMP environments for process development,…

JSR Life Sciences Acquires Exclusive Rights to SPF Technologies’ Chromassette® Platform

JSR Life Sciences has signed a technology licensing and joint development agreement for the Chromassette® technology with SPF Technologies, LLC, a private Somerville, MA-based company providing innovative solutions for biopharmaceutical manufacturing. “As a materials company that is breaking into the Life Sciences, we are continually looking for new technologies and trying to identify future trends,” said Eric R. Johnson, President of JSR Life Sciences.  “We see great potential for the Chromassette technology and its impact on the bioprocessing industry.” The…

MilliporeSigma Launches Viresolve® Pro Shield H for More Robust, Economical Parvovirus Removal

MilliporeSigma today launched the Viresolve® Pro Shield H for removal of parvoviruses from therapeutic protein feed streams. The new Viresolve® Pro Shield H is designed for use as a prefilter with Viresolve® Pro Devices for more robust, cost-economic viral clearance. Viresolve® Pro Shield H removes protein aggregates and impurities that foul virus filters in high pH and high conductivity monoclonal antibody (MAb) feed streams. Combined with Viresolve® Pro Device parvovirus retentive filters, the Viresolve® Pro Shield H significantly increases processing…

Rentschler-newfacility

Rentschler Doubles Manufacturing Capacity to Address Growing Demand for Biopharmaceuticals

Rentschler Biotechnologie GmbH, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the opening of a new facility with an capacity of two times 3,000 liters at the company’s site in Laupheim. This innovative Twin system consists of two stainless steel bioreactors for the manufacturing of cell culture-derived proteins and is complemented by directly connected equipment for protein purification. The system increases Rentschler’s manufacturing capacity for the second time within a year; a new 2,000 liter single-use…